{
  "generated_at": "2026-02-07T05:25:55Z",
  "company_id": "immatics",
  "company_name": "Immatics",
  "changes": [
    {
      "event_type": "trials_ingested",
      "created_at": null,
      "payload": {
        "trials_seen": 2,
        "inserted": 2,
        "updated": 0,
        "status_changed": 0,
        "bad_aliases": 0
      },
      "evidence_id": null,
      "asset_id": null,
      "trial_id": null
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "payload": {
        "nct_id": "NCT05958121",
        "linked_assets": 1
      },
      "evidence_id": 45,
      "asset_id": null,
      "trial_id": 42
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "payload": {
        "nct_id": "NCT05359445",
        "linked_assets": 1
      },
      "evidence_id": 46,
      "asset_id": null,
      "trial_id": 43
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "payload": {
        "nct_id": "NCT05958121",
        "title": "A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors"
      },
      "evidence_id": 45,
      "asset_id": null,
      "trial_id": 42
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "payload": {
        "nct_id": "NCT05359445",
        "title": "A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors."
      },
      "evidence_id": 46,
      "asset_id": null,
      "trial_id": 43
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": null,
      "payload": {
        "pipeline_page": "https://immatics.com/our-pipeline/",
        "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png",
        "assets_seen": 5
      },
      "evidence_id": 3,
      "asset_id": null,
      "trial_id": null
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "payload": {
        "asset": "IMA402",
        "indication": "Melanoma, gynecologic cancers, other solid cancers",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      },
      "evidence_id": 3,
      "asset_id": 18,
      "trial_id": null
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "payload": {
        "asset": "IMA402 + ICI",
        "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      },
      "evidence_id": 3,
      "asset_id": 19,
      "trial_id": null
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "payload": {
        "asset": "IMA401",
        "indication": "HNSCC, sqNSCLC, other solid cancers",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      },
      "evidence_id": 3,
      "asset_id": 20,
      "trial_id": null
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "payload": {
        "asset": "Undisclosed bispecific",
        "indication": "Undisclosed",
        "stage": "Preclinical",
        "therapeutic_area": "Oncology"
      },
      "evidence_id": 3,
      "asset_id": 21,
      "trial_id": null
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "payload": {
        "asset": "Undisclosed cell therapy",
        "indication": "Undisclosed",
        "stage": "Preclinical",
        "therapeutic_area": "Oncology"
      },
      "evidence_id": 3,
      "asset_id": 22,
      "trial_id": null
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "payload": {
        "asset": "IMA402"
      },
      "evidence_id": 3,
      "asset_id": 18,
      "trial_id": null
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "payload": {
        "asset": "IMA402 + ICI"
      },
      "evidence_id": 3,
      "asset_id": 19,
      "trial_id": null
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "payload": {
        "asset": "IMA401"
      },
      "evidence_id": 3,
      "asset_id": 20,
      "trial_id": null
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "payload": {
        "asset": "Undisclosed bispecific"
      },
      "evidence_id": 3,
      "asset_id": 21,
      "trial_id": null
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "payload": {
        "asset": "Undisclosed cell therapy"
      },
      "evidence_id": 3,
      "asset_id": 22,
      "trial_id": null
    }
  ]
}